Navigation Links
Factor Bioscience Granted First U.S. Patent for RNA-Based Reprogramming Technology
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- The United States Patent and Trademark Office today granted Factor Bioscience the first patent covering methods for reprogramming cells using RNA, a technology with wide-ranging applications in biological research and personalized medicine. The patented methods can transform patient skin cells into stem cells more rapidly, efficiently, and safely than previous techniques.

"Reprogramming is an amazing process, when it works," explains co-inventor Dr. Christopher Rohde, Chief Operating Officer and Director of High-Throughput Technologies. "However, previous methods were burdened by cumbersome protocols, poor reliability, and woeful inefficiency. Our RNA-reprogramming technology overcomes all of these limitations while being faster and safer than the best available techniques."

Excitement has been growing in the reprogramming field since Dr. Shinya Yamanaka's Nobel Prize-winning discovery in 2006 that infecting skin cells with a specific combination of viruses could reprogram them to a pluripotent stem-cell state. However, efforts to achieve the same goal without using the potentially mutation-causing viruses had, until this point, yielded mixed results. "Many researchers have attempted to develop a reliable DNA-free reprogramming method, and more than one have claimed success," says co-inventor Dr. Matt Angel, CEO. "In every case, the reported method turned out to be unreliable at best, and more often than not, completely irreproducible. The grant of the first patent covering reliable DNA-free reprogramming technology brings us one step closer to the development of therapeutics based on safely reprogrammed cells."

The methods developed by Dr. Angel's team can be used with a wide range of reprogramming factors and cell types, and the company is making chemically-defined, animal component-free versions of its products available for therapeutic applications. Dr. Angel's goal is to deploy the technology as widely as possible through a combination of products, services, and partnerships. "Factor Bioscience is a unique company, owned and operated entirely by scientists. The development of the first reliable RNA-reprogramming technology is the perfect example of what is possible in this environment."

About Factor Bioscience
Founded in 2011, Factor Bioscience develops nucleic-acid and cell-based research tools and therapeutics using its patented and patent-pending reprogramming and gene-editing technologies. For more information, visit www.factorbio.com, and follow us on Twitter at @factorbio.

The content of this press release is the sole responsibility of the authors and does not necessarily represent the official views of the USPTO.


'/>"/>
SOURCE Factor Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Announces 2012 Journal Impact Factor Highlights
2. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
3. Latest Cell Publication of OriGene and Peking University Collaborative Discovery of New iPSC Reprogramming Factors
4. New study identifies the role of a key growth factor in promoting formation of hair follicles and suggests a new therapeutic approach to treat baldness
5. Cell Culture Market (Media, Sera, Reagents, Serum-Free Media, Albumin, Growth Factors & Cytokines, Instruments, Bioreactors, Roller Bottle Equipment, T-Flasks And Cryostorage Equipment) - Global Industry Analysis, Size, Share, Growth, Trends And For
6. Researchers identify transcription factors that regulate retinal vascularization
7. ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory
8. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
9. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. The X factor in liver metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):